116 related articles for article (PubMed ID: 8675231)
41. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.
Lloyd A; Hickie I; Wakefield D; Boughton C; Dwyer J
Am J Med; 1990 Nov; 89(5):561-8. PubMed ID: 2146875
[TBL] [Abstract][Full Text] [Related]
42. Interferon-alpha regulation of lymphocyte function in systemic lupus erythematosus.
Sibbitt WL; Froelich CJ; Bankhurst AD
Clin Immunol Immunopathol; 1984 Jul; 32(1):70-80. PubMed ID: 6733982
[TBL] [Abstract][Full Text] [Related]
43. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy.
Mariani E; Facchini A; Honorati MC; Lalli E; Berardesca E; Ghetti P; Marinoni S; Nuzzo F; Astaldi Ricotti GC; Stefanini M
Clin Exp Immunol; 1992 Jun; 88(3):376-82. PubMed ID: 1535035
[TBL] [Abstract][Full Text] [Related]
44. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
45. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu EW; Huth TK; Hardcastle SL; Fuller K; Kaur M; Johnston S; Ramos SB; Staines DR; Marshall-Gradisnik SM
Int Immunol; 2014 Apr; 26(4):233-42. PubMed ID: 24343819
[TBL] [Abstract][Full Text] [Related]
46. Recombinant alpha-2a interferon treatment in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC): clinical and immunological evaluation.
Mezzaroma I; Avella A; Paganelli R; Ensoli B; d'Offizi G; Sirianni MC; Luzi G; Valdarchi C; Aiuti F
Allergol Immunopathol (Madr); 1991; 19(5):201-7. PubMed ID: 1811417
[TBL] [Abstract][Full Text] [Related]
47. Immunologic and psychosocial status in chronic fatigue syndrome.
Nas K; Cevik R; Batum S; Sarac AJ; Acar S; Kalkanli S
Bratisl Lek Listy; 2011; 112(4):208-12. PubMed ID: 21585130
[TBL] [Abstract][Full Text] [Related]
48. Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial.
Kaiser G; Jaeger H; Birkmann J; Poppinger J; Cummins JM; Gallmeier WM
AIDS; 1992 Jun; 6(6):563-9. PubMed ID: 1388878
[TBL] [Abstract][Full Text] [Related]
49. Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha.
Russell IJ; Vipraio GA; Michalek JE; Craig FE; Kang YK; Richards AB
J Interferon Cytokine Res; 1999 Aug; 19(8):969-78. PubMed ID: 10476945
[TBL] [Abstract][Full Text] [Related]
50. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
[TBL] [Abstract][Full Text] [Related]
51. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans.
Kutza J; Gratz I; Afshar M; Murasko DM
Anesth Analg; 1997 Oct; 85(4):918-23. PubMed ID: 9322480
[TBL] [Abstract][Full Text] [Related]
52. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
53. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients.
Vacher-Coponat H; Brunet C; Lyonnet L; Bonnet E; Loundou A; Sampol J; Moal V; Dussol B; Brunet P; Berland Y; Dignat-George F; Paul P
Nephrol Dial Transplant; 2008 Apr; 23(4):1406-14. PubMed ID: 18029366
[TBL] [Abstract][Full Text] [Related]
54. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
55. Lymphocyte phenotype and function in the chronic fatigue syndrome.
Straus SE; Fritz S; Dale JK; Gould B; Strober W
J Clin Immunol; 1993 Jan; 13(1):30-40. PubMed ID: 8095270
[TBL] [Abstract][Full Text] [Related]
56. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
57. Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males.
Miles EA; Banerjee T; Wells SJ; Calder PC
Nutrition; 2006 May; 22(5):512-9. PubMed ID: 16600816
[TBL] [Abstract][Full Text] [Related]
58. Influence of interferon-alpha on lymphocyte subpopulations in Behçet's disease.
Treusch M; Stübiger N; Vonthein R; Baur M; Koch S; Günaydin I; Kanz L; Zierhut M; Kötter I
Adv Exp Med Biol; 2003; 528():533-5. PubMed ID: 12918758
[No Abstract] [Full Text] [Related]
59. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Rivas JL; Palencia T; Fernández G; García M
Front Immunol; 2018; 9():1028. PubMed ID: 29867995
[TBL] [Abstract][Full Text] [Related]
60. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells.
Jewett A; Bonavida B
J Clin Immunol; 1995 Jan; 15(1):35-44. PubMed ID: 7759599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
